Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4327385, 8 pages
https://doi.org/10.1155/2017/4327385
Research Article

Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B

1Department of Medicine, Division of Gastroenterology and Hepatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
4Office of Research Academic and Innovation, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
5Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
6National Center for Genetic Engineering and Biotechnology, Pathumthani, Thailand
7Department of Medicine, Division of Nephrology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence should be addressed to Abhasnee Sobhonslidsuk; ht.ca.lodiham@bos.eensahba

Received 24 June 2017; Accepted 3 October 2017; Published 29 October 2017

Academic Editor: Haruki Komatsu

Copyright © 2017 Abhasnee Sobhonslidsuk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. K. Sarin, M. Kumar, G. K. Lau et al., “Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update,” Hepatology International, vol. 10, no. 1, pp. 1–98, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. N. A. Terrault, N. H. Bzowej, K.-M. Chang, J. P. Hwang, M. M. Jonas, and M. H. Murad, “AASLD guidelines for treatment of chronic hepatitis B,” Hepatology, vol. 63, no. 1, pp. 261–283, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of chronic hepatitis B virus infection,” Journal of Hepatology, vol. 57, no. 1, pp. 167–185, 2013. View at Publisher · View at Google Scholar
  4. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years,” Gastroenterology, vol. 131, no. 6, pp. 1743–1751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Buti, S. Fung, E. Gane et al., “Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years,” Hepatology International, vol. 9, no. 2, pp. 243–250, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Buti, N. Tsai, J. Petersen et al., “Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection,” Digestive Diseases and Sciences, vol. 60, no. 5, pp. 1457–1464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. X. B. Wang, X. C. Zhu, X. Y. Huang, W. J. Ye, and L. X. Wang, “Fanconi syndrome due to prolonged use of low-dose adefovir,” Journal of Research in Medical Sciences, vol. 20, no. 4, pp. 416–419, 2015. View at Google Scholar
  8. M. Tanaka, F. Suzuki, Y. Seko et al., “Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B,” Journal of Gastroenterology, vol. 49, no. 3, pp. 470–480, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Shimizu, A. Hiraoka, H. Yamago et al., “Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy,” Hepatology Research, vol. 44, no. 11, pp. 1081–1087, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Shimizu, N. Furusyo, H. Ikezaki et al., “Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B,” World Journal of Gastroenterology, vol. 21, no. 7, pp. 2116–2123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-T. Law, K. K. Li, and Y. Y. Ho, “Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - Is there a safe dose?” Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 2, pp. 128–131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. K. Jung, J. E. Yeon, J. H. Choi et al., “Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient,” Gut and Liver, vol. 4, no. 3, pp. 389–393, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Q. Luo, Y. Deng, C. Feifei et al., “Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis,” Medicine (United States), vol. 95, no. 50, p. e5578, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. C. L. N. Woodward, A. M. Hall, I. G. Williams et al., “Tenofovir-associated renal and bone toxicity,” HIV Medicine, vol. 10, no. 8, pp. 482–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Verhelst, M. Monge, J.-L. Meynard et al., “Fanconi syndrome and renal failure induced by tenofovir: A first case report,” American Journal of Kidney Diseases, vol. 40, no. 6, pp. 1331–1333, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Andrade-Fuentes, J. A. Mata-Marín, J. I. López-De León, B. Manjarrez-Téllez, J. L. S. Ramírez, and J. Gaytan-Martínez, “Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico,” AIDS Patient Care and STDs, vol. 29, no. 4, pp. 181–185, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. F. Lok, B. J. Mcmahon, R. S. Brown et al., “Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis,” Hepatology, vol. 63, no. 1, pp. 284–306, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Gara, X. Zhao, M. T. Collins et al., “Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 11, pp. 1317–1325, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Tien, J. J. Xu, L. S. Chan et al., “Long-term treatment with tenofovir in asian-american chronic hepatitis B patients is associated with abnormal renal phosphate handling,” Digestive Diseases and Sciences, vol. 60, no. 2, pp. 566–572, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Sobhonslidsuk, J. Wanichanuwat, P. Numthavaj et al., “Nucleotide analogue-related proximal renal tubular dysfunction during long-term treatment of chronic hepatitis B: A cross-sectional study,” Gastroenterology Research and Practice, vol. 2016, Article ID 2952635, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. K. K. Mugwanya, C. Wyatt, C. Celum et al., “Reversibility of glomerular renal function decline in HIV-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis,” Journal of Acquired Immune Deficiency Syndromes, vol. 71, no. 4, pp. 374–380, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. J. L. Casado, J. M. Del Rey, S. Bañón et al., “Changes in kidney function and in the rate of tubular dysfunction after tenofovir withdrawal or continuation in HIV-infected patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 72, no. 4, pp. 416–422, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Peyriere, A. Cournil, M.-L. Casanova, S. Badiou, J.-P. Cristol, and J. Reynes, “Long-term follow-up of proteinuria and estimated glomerular filtration rate in HIV-infected patients with tubular proteinuria,” PLoS ONE, vol. 10, no. 11, Article ID e0142491, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Bonjoch, P. Echeverría, N. Perez-Alvarez et al., “High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy,” Antiviral Research, vol. 96, no. 1, pp. 65–69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Cha, A. R. Besignano-Long, N. Rothberger, and B. Shah, “Reversibility of renal dysfunction after discontinuation of tenofovir,” Journal of the American Pharmacist Association, vol. 56, no. 3, pp. 280–283, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Viganò, A. Brocchieri, A. Spinetti et al., “Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal,” Journal of Clinical Virology, vol. 61, no. 4, pp. 600–603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Labarga, P. Barreiro, L. Martin-Carbonero et al., “Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir,” AIDS, vol. 23, no. 6, pp. 689–696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Del Palacio, S. Romero, and J. L. Casado, “Proximal tubular renal dysfunction or damage in HIV-infected patients,” AIDS Reviews, vol. 14, no. 3, pp. 179–187, 2012. View at Google Scholar · View at Scopus
  29. A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Chantler, “Kidney diseases in children,” in Disease of the kidney, R. Schrier and C. Gottschalk, Eds., pp. 2379–2403, Little Brown, Boston, MA, 1993. View at Google Scholar
  31. G. Fogazzi and G. Garigali, “Urinalysis,” in Comprehensive Clinical Nephrology, R. Johnson, J. Feehally, and J. Floege, Eds., pp. 39–52, Elsevir Saunders, Canada, 2015. View at Google Scholar
  32. F. A. Post, C. M. Wyatt, and A. Mocroft, “Biomarkers of impaired renal function,” Current Opinion in HIV and AIDS, vol. 5, no. 6, pp. 524–530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Miyata, M. Jadoul, K. Kurokawa, and C. Van Ypersele De Strihou, “β-2 microglobulin in renal disease,” Journal of the American Society of Nephrology, vol. 9, no. 9, pp. 1723–1735, 1998. View at Google Scholar · View at Scopus
  34. I. Oboho, A. Abraham, L. Benning et al., “Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS),” Journal of Acquired Immune Deficiency Syndromes, vol. 62, pp. 388–395, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Dahlin, M. Wittwer, M. De La Cruz et al., “A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome,” Pharmacogenetics and Genomics, vol. 25, no. 2, pp. 82–92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Jafari, H. Khalili, and S. Dashti-Khavidaki, “Tenofovir-induced nephrotoxicity: Incidence, mechanism, risk factors, prognosis and proposed agents for prevention,” European Journal of Clinical Pharmacology, vol. 70, no. 9, pp. 1029–1040, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. H. J. Jeong, J. M. Lee, T. H. Lee et al., “Two cases of hypophosphatemic osteomalacia after long-term low dose adefovir therapy in chronic hepatitis B and literature review,” Journal of Bone Metabolism, vol. 21, no. 1, pp. 76–83, 2014. View at Publisher · View at Google Scholar
  38. P. Maggi, V. Montinaro, A. Leone et al., “Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study,” Journal of Antimicrobial Chemotherapy, vol. 70, no. 4, pp. 1150–1154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. X.-Y. Wang and H.-S. Chen, “Emerging antivirals for the treatment of hepatitis B,” World Journal of Gastroenterology, vol. 20, no. 24, pp. 7707–7717, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Sobhonslidsuk, J. Wanichanuwat, P. Numthavaj et al., “809 reversal of proximal renal tubular dysfunction after nucleotide analogue withdrawal in chronic hepatitis B,” Gastroenterology, vol. 150, no. 4, pp. S1048–S1049, 2016. View at Publisher · View at Google Scholar